報價延遲最少15分鐘:2025/07/21 06:35 EDT
盤前時段
|
||||
|
2.04 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.95
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.37/--
|
|
企業價值
81.31M
|
| 資產負債 |
|
每股賬面淨值
1.45
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
0.12
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/21 06:35 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. |
